DEF 14A: NovaBay Pharmaceuticals Seeks Stockholder Approval for Key Proposals Including Reverse Stock Split

NovaBay Pharmaceuticals is asking stockholders to vote on several proposals at its upcoming annual meeting, including the election of directors, ratification of the accounting firm, approval of share issuances related to warrant exercises and convertible notes, and a reverse stock split.

Summary

• NovaBay Pharmaceuticals is holding its 2024 Annual Meeting of Stockholders on May 28, 2024, virtually.
• Stockholders will vote on six proposals, including the election of three Class II directors, ratification of WithumSmith+Brown, PC as the independent registered public accounting firm, and approval of the issuance of common stock upon the exercise of Series C warrants and the conversion of unsecured convertible notes and Series D warrants.
• The company is also seeking approval for a reverse stock split at a ratio of not less than 1-for-10 and not more than 1-for-35.
• The Board of Directors recommends voting FOR all proposals.
• The company had full year net product revenue of $14.7 million in 2023, including $7.8 million from Avenova Spray.
• Gross profit was $7.9 million in 2023, with a gross profit margin of 53.6%.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is taking steps to improve its financial position through divestitures and financing activities, it also faces challenges related to stock price compliance and potential dilution. The need for a reverse stock split and the going concern warning temper the positive aspects.

Positives

• The sale of DERMAdoctor streamlines the business to focus on the core eyecare business.
• The company has taken steps to further its environmental, social and governance (ESG) practice.
• The company has a longstanding commitment to effective governance of its business and affairs for the benefit of stockholders.

Negatives

• The company's stock price is below the NYSE American minimum, necessitating a reverse stock split proposal.
• Failure to obtain stockholder approval for the issuance of shares underlying the unsecured convertible notes by September 25, 2024, will result in the full amount of $525 thousand becoming immediately due and payable.
• Existing stockholders will experience dilution if the Series C warrants, unsecured convertible notes, and Series D warrants are exercised or converted.

Risks

• The reverse stock split may not increase the stock price and could lead to a decrease in overall market capitalization.
• The reverse stock split may decrease the liquidity of the common stock.
• The company may fail to realize the expected benefits of the reverse stock split.
• The company's expenses are expected to continue to exceed revenues.
• The company's planned operations raise substantial doubt about its ability to continue as a going concern.

Future Outlook

The company expects its expenses to continue to exceed revenues as it continues its commercialization efforts and plans to use additional authorized shares resulting from the Reverse Stock Split to continue to pursue its historical financing strategy of raising additional capital in order to fund its operations and meet its ongoing obligations.

Industry Context

The document does not provide specific details on how NovaBay's announcement relates to broader industry trends or competitors beyond mentioning that the Compensation Committee reviews market information about the compensation of executive officers at similarly-sized biotechnology companies within its geographic region, or peer group companies.

Corporate Governance

Related Party Transactions

• The DERMAdoctor acquisition involved related parties, including Dr. Audrey Kunin and Dr. Jeff Kunin.
• The 2023 Private Placement involved voting commitments from related parties, including Mr. Fu and Pioneer Hong Kong, with Mr. Sean Zheng serving as the Head of Investment Department of Pioneer and Mr. Wu historically serving as the Non-Executive Director of Pioneer.

Stakeholder Impact

• Shareholders will be impacted by the reverse stock split, potential dilution from warrant exercises and convertible note conversions, and the company's efforts to maintain NYSE American listing.
• Employees may be impacted by the company's restructuring and cost-cutting measures.
• Customers may be impacted by the company's focus on its core eyecare business following the DERMAdoctor divestiture.
• Creditors are impacted by the terms of the Secured Convertible Notes and the issuance of Unsecured Convertible Notes.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on May 28, 2024.
• The Board will determine whether to effect the reverse stock split and at what ratio, if Proposal Five is approved.
• The company will file a registration statement covering the resale of shares of Common Stock underlying the Series C Warrants by June 21, 2024.
• The company will file a registration statement covering the resale of shares of Common Stock underlying the Unsecured Convertible Notes and the Series D Warrant within 60 days after stockholder approval is received.
• The company will continue to seek stockholder approval every four months until such proposal is approved.

Key Dates

Keywords

Reverse Stock Split, Proxy Statement, Share Issuance, Warrants, Convertible Notes, DERMAdoctor, Annual Meeting, NovaBay, Stockholders